Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy.
about
SOX2 immunity and tissue resident memory in children and young adults with glioma.Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.Genomic landscape of high-grade meningiomas.Immune Checkpoint Inhibitors in Gliomas.Cancer Immunogenomics: Computational Neoantigen Identification and Vaccine Design.Applied Cancer Immunogenomics: Leveraging Neoantigen Discovery in Glioblastoma.DNA Damage and Repair Biomarkers of Immunotherapy Response.Replicative DNA polymerase defects in human cancers: Consequences, mechanisms, and implications for therapy.ClonEvol: clonal ordering and visualization in cancer sequencing.Successful Treatment of a Patient with Glioblastoma and a Germline POLE Mutation: Where Next?Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures.Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment.Comprehensive Analysis of Hypermutation in Human Cancer.PD-1 inhibitors in endometrial cancer.Neoantigen Targeting-Dawn of a New Era in Cancer Immunotherapy?Biological and therapeutic implications of multisector sequencing in newly diagnosed glioblastomas.Immunotherapy for brain tumors: understanding early successes and limitations.Advances in immunotherapeutic research for glioma therapy.Combining DNA damaging therapeutics with immunotherapy: more haste, less speed.Precision Immuno-Oncology: Prospects of Individualized Immunotherapy for Pancreatic Cancer.Immunotherapies for malignant glioma.Unwrapping the genomic characteristics of urothelial bladder cancer and successes with immune checkpoint blockade therapy.Functional Analysis of Cancer-Associated DNA Polymerase ε Variants in Saccharomyces cerevisiae.Tumour heterogeneity and resistance to cancer therapies.Targeting Neoantigens in Glioblastoma: An Overview of Cancer Immunogenomics and Translational Implications.Exome analysis of carotid body tumor.Distinct mutational signatures characterize concurrent loss of polymerase proofreading and mismatch repair.Pediatric High Grade Gliomas in the Context of Cancer Predisposition Syndromes.Durable Complete Responses in Some Recurrent High Grade Glioma Patients Treated with Toca 511 & Toca FC.Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right TimeThe DNA damage response in immunotherapy and radiation
P2860
Q38373829-17004E60-B5AF-41D4-B68A-C4F38368F765Q38635512-98E018AD-117B-4C01-AB63-67E2C1E0D230Q38676440-06F8A456-3098-4AAA-AF42-72389CBB4F6CQ38743793-D52D38E3-1B2D-4867-B22C-630738F94673Q38847147-7591B30B-9AC1-4899-9D62-B8945A6F6274Q39243060-01F24285-1790-4857-A9CF-83E9E7840947Q39384263-B22CD2D8-543F-4E96-9C8E-F527F73CE515Q39421725-9CE1F960-ACF4-457C-826F-7E35A6BB1E7EQ42696942-A6B8BFD9-8B87-476A-860B-1BF77FB1D93DQ42745976-CD92EC14-83AE-4F31-B926-C2080EA026F9Q46037449-2D0BC024-75AF-4EFC-9521-9E46EE865D1FQ46410671-D66C8828-D0DA-47CC-884B-65C6A30057D1Q46592106-AF28977A-7708-4CE2-8483-07A26027DAE4Q47140563-7AE11E22-B4E2-4486-A93B-AC4C58FEA9F6Q47221163-361FEA29-AB25-4AB2-85D9-3D96EAA62FBFQ47304287-058C6CC5-9CAF-4ACE-B577-77AAEB47D153Q47555498-A27E4AD5-E391-416E-B727-B9DBF033A8BFQ47569046-46263821-C7DD-4B7F-A9E4-47AB8DAA2FF7Q47621538-CEDE3045-D2AA-4593-80DD-0F4FAE3F2849Q47701712-885A401E-48EE-435E-8FE6-7AFBDD5EC979Q47915209-91368646-B911-4F41-89DD-63EFFB6010FFQ49865882-F97C8B32-A318-417A-90CE-31304905B0EFQ49911660-F3A4EB53-FC49-486A-A9A0-0520AEB42837Q50112440-729080D7-C507-4D55-A074-70AA841CA381Q50130464-B8306861-FD09-4D83-9CA3-A9D4E32F2972Q52674249-AD831E95-81D4-4825-B445-88891BDCEC40Q55025484-49AD8FEB-C5BC-40CE-831B-AA25B4693BB4Q55277238-373F4A31-4A01-4ED9-951D-00D3C96FCBD3Q55457095-F922053B-B569-4F14-9D3E-0334D34104CBQ57486475-F7A24880-3B25-452C-85B5-3F1B3C8E698EQ58119182-9C920CB7-10F0-4DB0-850C-4680D0C165E3
P2860
Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Immunogenomics of Hypermutated ...... kpoint Blockade Immunotherapy.
@en
Immunogenomics of Hypermutated ...... kpoint Blockade Immunotherapy.
@nl
type
label
Immunogenomics of Hypermutated ...... kpoint Blockade Immunotherapy.
@en
Immunogenomics of Hypermutated ...... kpoint Blockade Immunotherapy.
@nl
prefLabel
Immunogenomics of Hypermutated ...... kpoint Blockade Immunotherapy.
@en
Immunogenomics of Hypermutated ...... kpoint Blockade Immunotherapy.
@nl
P2093
P2860
P1433
P1476
Immunogenomics of Hypermutated ...... kpoint Blockade Immunotherapy.
@en
P2093
Arie Perry
Christina Tsien
Christopher A Miller
Cole Ferguson
Edward Chang
Elaine R Mardis
Gavin P Dunn
George Ansstas
Ian G Dorward
Ravindra Uppaluri
P2860
P304
P356
10.1158/2159-8290.CD-16-0575
P577
2016-09-28T00:00:00Z